Q4 2023 · 13F-HR
Bain Capital Life Sciences Investors, LLCholdings as filed
Filed 2024-02-13 · accession 0000950123-24-001898
$1.04B
Reported value
27
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $263.3M | 25.2% | 3,577,267 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $117.0M | 11.2% | 10,473,913 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $109.5M | 10.5% | 3,904,319 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $77.0M | 7.38% | 1,332,545 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $75.1M | 7.20% | 324,619 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $66.9M | 6.41% | 14,232,751 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $45.4M | 4.35% | 2,000,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $36.6M | 3.51% | 8,061,719 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $31.9M | 3.06% | 1,112,396 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $28.6M | 2.74% | 2,892,663 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $25.1M | 2.40% | 400,197 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $21.4M | 2.05% | 2,749,808 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $20.1M | 1.93% | 8,663,673 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $19.2M | 1.84% | 3,130,422 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $18.8M | 1.80% | 1,822,883 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $15.6M | 1.49% | 1,431,058 | Common | SOLE |
| 98420X103 | ASNSUSD | X4 PHARMACEUTICALS INC | $14.2M | 1.36% | 16,915,784 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $9.7M | 0.93% | 3,000,000 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $9.3M | 0.89% | 1,642,210 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $7.6M | 0.73% | 1,937,207 | Common | SOLE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $7.6M | 0.73% | 2,485,638 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC | $6.2M | 0.60% | 8,434,560 | Common | SOLE |
| 63909J108 | NAUT | NAUTILUS BIOTECHNOLOGY INC | $6.0M | 0.57% | 2,000,000 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $5.7M | 0.55% | 1,331,801 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $3.7M | 0.35% | 3,500,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $1.5M | 0.15% | 2,805,413 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $313,000 | 0.03% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.